Laurus Labs (LAURUSLABS) Q1 24/25 earnings summary

Executive summary

• Embarked on a major rebranding initiative, shifting toward a diversified CMO-focused model and expanded global positioning in pharma and biotech manufacturing services.

• Q1 FY25 revenue at ₹1,195 Cr, up 1% year-over-year, with growth in API (Onco-led) and ARV demand offset by subdued CDMO delivery.

• Board approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2024, with statutory auditor review and unmodified conclusion.

• Appointment of Mr. Ramesh Subrahmanian as an Additional Independent Director for a five-year term, subject to shareholder approval.

• Q1 FY25 began positively, with resilience in financial health and momentum in key CDMO clinical projects, despite pricing pressure in generic APIs.

Financial highlights

• Q1 FY25 revenue grew 1% year-over-year to INR 1,195 crore; sequential decline from Q4 FY24.

• Gross margin improved to 55.1%, supported by product mix, cost savings, and process improvements.

• EBITDA for Q1 at INR 171 crore (14.3% margin), with subdued margins due to lower asset utilization and growth investments.

• Net profit at ₹13 Cr, down 48% YoY and 83% QoQ; EPS at 0.2.

• Net debt stood at INR 2,633 crore; CapEx investment of INR 125 crore in Q1.

Outlook and guidance

• Performance expected to improve in H2 FY25, with commercial deliveries for key late-phase NCE projects in Q4.

• FY25 projected as a strong year, with FY26 expected to be even better as new assets (animal health, crop protection) come online.

• ARV franchise revenue expected to remain stable at INR 2,400–2,500 crore annually, but as a percentage of total revenue, ARV contribution will decline as other segments grow.

• Confident in maintaining 20% EBITDA margin guidance for FY25.

• Growth in FY25 to be driven by medium/long-term contracts, late-phase NCE projects, and new assets coming online.